Guardant steps into a new arena

Guardant steps into a new arena

Source: 
EP Vantage
snippet: 

One of the groups locked in battle for dominance of the pan-cancer blood test market has just pulled ahead in a new setting. Today Guardant Health launched in the US what it claims is the first liquid biopsy that can track a patient’s response to immunotherapy or targeted drugs, and do so more quickly than current methods used by oncologists.